{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:45:15Z","timestamp":1784958315910,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.breast.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T19:47:56Z","timestamp":1509565676000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy\u00a0\u00b1\u00a0trastuzumab"],"prefix":"10.1016","volume":"37","author":[{"given":"Dorothy M.","family":"Gujral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.jacc.2015.04.012","article-title":"Subclinical cardiotoxicity associated with cancer therapy: early detection and future directions","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2017.10.010_bib5","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.010_bib6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2017.10.010_bib8","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.breast.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00a0\u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.breast.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.breast.2017.10.010_bib15","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2017.10.010_bib16","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2017.10.010_bib17","first-page":"936","article-title":"Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer","volume":"35","author":"Liu","year":"2013","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.breast.2017.10.010_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.breast.2017.10.010_bib19","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.010_bib20","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy","volume":"185","author":"Santos","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.breast.2017.10.010_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/jpet.115.225375","article-title":"Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy","volume":"355","author":"Chen","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.breast.2017.10.010_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","article-title":"Cardioprotective role of \u03b2-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis","volume":"91","author":"Yun","year":"2015","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.breast.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib25","first-page":"145","article-title":"Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group","volume":"3","author":"Seymour","year":"1999","journal-title":"Cancer Prev Control"},{"key":"10.1016\/j.breast.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","article-title":"Early anthracycline cardiotoxicity","volume":"65","author":"Bristow","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.breast.2017.10.010_bib27","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2017.10.010_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2017.10.010_bib30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617305982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617305982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:38:21Z","timestamp":1760776701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977617305982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":31,"alternative-id":["S0960977617305982"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.010","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy\u00a0\u00b1\u00a0trastuzumab","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}